Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
Portfolio Pulse from Vandana Singh
Marinus Pharmaceuticals' stock plummeted after its oral seizure drug ganaxolone failed to meet the primary endpoint in a Phase 3 trial for tuberous sclerosis complex. The company is exploring strategic alternatives and reducing costs, including workforce cuts.
October 24, 2024 | 4:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Marinus Pharmaceuticals' stock fell sharply after its oral seizure drug ganaxolone failed to meet the primary endpoint in a Phase 3 trial for tuberous sclerosis complex. The company is now exploring strategic alternatives and reducing costs, including workforce cuts.
The failure of the Phase 3 trial for ganaxolone is a significant setback for Marinus Pharmaceuticals, leading to a drastic stock price drop. The company's decision to explore strategic alternatives and reduce costs, including workforce cuts, indicates a major shift in strategy due to the trial's outcome.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100